Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4156986 | 0.76 | NAAA (0.46) | NAAASIGMAR1IDO1AGXT | |
| SCHEMBL18287587 | 0.76 | NAAA (0.37) | NAAAMAPK1SIGMAR1IDO1AGXT | |
| SCHEMBL18615761 | 0.73 | NAAA (0.54) | NAAAIDO1AGXTKDM4E | |
| SCHEMBL24228464 | 0.72 | NAAA (0.45) | NAAAHTTKDM4EMAPTNPC1 | |
| SCHEMBL24620048 | 0.71 | NAAA (0.47) | NAAASIGMAR1IDO1AGXT | |
| SCHEMBL18855492 | 0.71 | NAAA (0.47) | NAAAIDO1AGXTTACR1 | |
| SCHEMBL22454181 | 0.71 | NAAA (0.56) | NAAAIDO1AGXTHTTKDM4E | |
| SCHEMBL22006160 | 0.71 | REN (0.44) | NAAAMAPK1SIGMAR1IDO1AGXT | |
| SCHEMBL17803300 | 0.71 | REN (0.44) | NAAAMAPK1SIGMAR1IDO1AGXT | |
| SCHEMBL16685531 | 0.71 | NAAA (0.49) | NAAAIDO1AGXTHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150314-A1 | TRIOXACARCINS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150314-A1 | TRIOXACARCINS AND USES THEREOF | PCSK9, PCSK7, ABCC9 | NAAA 1790/4885MAPK1 4393/4885SIGMAR1 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.